INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

NEWTOWN, Pa., Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus") (NASDAQ: ARCT), resulting from allegations of providing potentially misleading business information to the investing public.

If you have non-public information that could assist in the Arcturus Investigation or if you are an Arcturus investor who suffered a loss and would like to learn more, you can provide your information HERE .

You can also contact attorney Eric Lechtzin of Edelson Lechtzin LLP by calling 844-563-5550 or via e-mail at [email protected] .

THE COMPANY:

Arcturus Therapeutics specializes in creating mRNA vaccines and therapies.

THE ALLEGED WRONGDOING:

On October 22, 2025, Arcturus reported Phase 2 trial results for its inhaled mRNA therapy ARCT-032 in cystic fibrosis, showing no meaningful improvement in lung function (FEV1). Following the announcement, the company's stock dropped 50.17% to close at $11.54 per share.

ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation alleging violations of the federal antitrust laws, fiduciary duties under ERISA, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.

For more information, please contact:

Marc H. Edelson, Esq.
Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: [email protected]
Email: [email protected]
Web: www.edelson-law.com 

This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

SOURCE Edelson Lechtzin LLP